Natco Pharma Ltd has received approval for generic sofosbuvir tablets from Drugs the Controller General of India.
The Hyderabad-based company was the first to received approval for this drug, according to a release.
Sofosbuvir is a medicine used for chronic hepatitis C infection and sold globally by Gilead Sciences, Inc.,
under its brand Sovaldi. Natco will market generic sofosbuvir under its brand Hepcinat and through strategic partners in India.
Natco plans to price its generic medicine at an Rs 19,900 for a bottle of 28 tablets and expects to
Launch in India very soon.
Natco had recently signed a non-exclusive licensing agreement with Gilead Sciences, to manufacture and sell generic versions of its chronic hepatitis C medicines in 91 developing countries.
The company’s scrip surged 14.78 per cent on the Bombay Stock Exchange on Thursday to end at Rs 2056.